title: Ubiquitin-proteasomal degradation of antiapoptotic survivin facilitates induction of apoptosis in prostate cancer cells by pristimerin.
abstract: Pristimerin (PM), a quinonemethide triterpenoid, is a promising anticancer agent with potent antiproliferative and apoptosis-inducing activities against cancer cell lines. However, the anticancer activity and mechanisms of PM in prostate cancer cells have not been adequately investigated. Here we report that the degradation of survivin plays an important role in the antiproliferative and proapoptotic effects of PM in carcinoma of the prostate (CaP) cell lines. Treatment with PM inhibited proliferation and induced apoptosis in LNCaP and PC-3 cells as characterized by the loss of cell viability and an increase in Annexin V-binding and cleavage of PARP-1, respectively. The antiproliferative and apoptosis-inducing effects of PM were associated with the inhibition of cell cycle regulatory proteins, antiapoptotic survivin and members of the Bcl-2 family. Data showed that response to PM is regulated by survivin since overexpression of survivin rendered CaP cells resistant to PM. Furthermore, downregulation of survivin by PM was mediated through the ubiquitin-proteasomal degradation. Together, these data demonstrate that pristimerin inhibits proliferation and induces apoptosis in CaP cells by abolishing survivin through the ubiquitin-proteasome pathway.
authors.affiliation: Department of Surgery, Henry Ford Health System, Detroit, MI 48202, USA.
authors.forename: Yong Bo
authors.initials: YB
authors.lastname: Liu
authors.affiliation: Department of Surgery, Henry Ford Health System, Detroit, MI 48202, USA.
authors.forename: Xiaohua
authors.initials: X
authors.lastname: Gao
authors.affiliation: Department of Surgery, Henry Ford Health System, Detroit, MI 48202, USA.
authors.forename: Dorrah
authors.initials: D
authors.lastname: Deeb
authors.affiliation: Department of Medical Genetics, Henry Ford Health System, Detroit, MI 48202, USA.
authors.forename: Chris
authors.initials: C
authors.lastname: Brigolin
authors.affiliation: Department of Internal Medicine, Henry Ford Health System, Detroit, MI 48202, USA.
authors.forename: Yiguan
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Internal Medicine, Henry Ford Health System, Detroit, MI 48202, USA.
authors.forename: Jiajiu
authors.initials: J
authors.lastname: Shaw
authors.affiliation: Department of Medical Genetics, Henry Ford Health System, Detroit, MI 48202, USA.
authors.forename: Kirit
authors.initials: K
authors.lastname: Pindolia
authors.affiliation: Department of Surgery, Henry Ford Health System, Detroit, MI 48202, USA.
authors.forename: Subhash C
authors.initials: SC
authors.lastname: Gautam
mesh_terms: D017209:Apoptosis; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000378:metabolism*; D008297:Male; D053978:Pentacyclic Triterpenes; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology*; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism*; D000077022:Survivin; D014315:Triterpenes / Q000494:pharmacology*; D025801:Ubiquitin / Q000378:metabolism*
chemical_list: C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D053978:Pentacyclic Triterpenes; D000077022:Survivin; D014315:Triterpenes; D025801:Ubiquitin; D046988:Proteasome Endopeptidase Complex; C061553:ATP dependent 26S protease; C050414:celastrol